Trial Profile
Clinical study to examine the efficacy of the intravitreal injection of anti-VEGF antibody (Avastin) for intraocular neovascular disease and macular edema
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Diabetic retinopathy; Macular degeneration; Neovascular glaucoma; Retinal vein occlusion
- Focus Therapeutic Use
- 29 Jan 2017 Status changed from recruiting to completed.
- 24 Jul 2014 New trial record